Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features

NCT00103207 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.

NCT NCT00103207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00103207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features
Lead sponsor
Eastern Cooperative Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
October 13, 2005
Completion date
August 31, 2012
Enrollment
72 (actual)
Sites
157

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer